Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | PGR | P06401 | 2/20 | 0.61 |
| ▸ | ESRRG | P62508 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | HTR6 | P50406 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8915491 | 1.00 | ESR1 (0.61) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL3781211 | 1.00 | ESR1 (0.61) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL9857160 | 0.93 | ESR1 (0.62) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL9857866 | 0.93 | ESR1 (0.62) | ESR1ESR2MAPTMEN1TP53 | |
| Piperidine SCHEMBL9857095 | 0.92 | ESR1 (0.53) | ESR1ESR2MAPTMEN1TP53 | |
| Piperidine SCHEMBL9857603 | 0.92 | ESR1 (0.53) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL9857990 | 0.92 | ESR1 (0.70) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL9856952 | 0.90 | ESR1 (0.50) | ESR1ESR2MAPTMEN1TP53 | |
| Miproxifene SCHEMBL3781209 | 0.89 | ESR1 (0.69) | ESR1ESR2MAPTMEN1TP53 | |
| Miproxifene SCHEMBL3781215 | 0.89 | ESR1 (0.69) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346800-A1 | REDUCTION OF THE INCIDENCE OR RECURRENCE OF BREAST CANCER IN POSTMENOPAUSAL WOMEN TREATED WITH INTRAVAGINAL SEX STEROID PRECURSOR | ENDORECHERCHE, INC. (CA) | 2023-11-02 | — | — | US | claimed |
| US-11690852-B2 | Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor | ENDORECHERCHE. INC. | 2023-07-04 | — | — | US | claimed |
| US-20220313703-A1 | REDUCTION OF THE INCIDENCE OR RECURRENCE OF BREAST CANCER IN POSTMENOPAUSAL WOMEN TREATED WITH INTRAVAGINAL SEX STEROID PRECURSOR | ENDORECHERCHE, INC. (CA) | 2022-10-06 | — | — | US | claimed |
| EP-1483401-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | claimed |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-1728791-A1 | COMPOSITION FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1483401-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-02-27 | — | — | US | disclosed |
| EP-0272330-B1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-4897503-A | ANTITUMOR AGENTS; TREATING MAMMARY CANCER AND ANOVULATORY INFERTILITY | TAIHO PHARMACEUTICAL (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0272330-A1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ESR1, BRCA1, KISS1R | ESR1 1/4885ESR2 8/4885MAPT 883/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | ESR1 1848/4885ESR2 2372/4885MAPT 2574/4885 |
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | ESR1 3679/4885ESR2 2920/4885MAPT 945/4885 |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | PDCD1, CD274, PTPN1 | ESR1 1896/4885ESR2 3155/4885MAPT 2338/4885 |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | ESR1 2/4885ESR2 8/4885MAPT 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.